Experience: - Women's Health (Vasomotor Symptoms (VMS) /Hot Flashes (HF) associated with menopause)- Rare diseases / Gene therapy * Fezolinetant was submitted to the FDA in June 2022. In May 2023, the FDA approved Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause.

Experience: - Immunology (Inflammatory Bowel Disease (IBD): Crohn’s disease (CD)) - Neuroscience (Alzheimer's Disease (AD), Cognitive Impairment Associated with Schizophrenia (CIAS), Multiple Sclerosis (MS), Spinal Cord Injury (SCI), Stroke) * Zinbryta (Daclizumab High-Yield Process) was approved for the treatment of relapsing forms of multiple sclerosis (RMS) in the US in May, 2016 and EU in July, 2016.

Experience: - Immunology & Respiratory (Biosimilar products, Rheumatoid Arthritis (RA)) - Neuroscience (Schizophrenia, Bipolar mania, Bipolar depression, MDD, Negative symptoms of schizophrenia) * Saphris® (asenapine) was approved for treatment of schizophrenia, acute treatment of manic or mixed episodes associated with bipolar I disorder in the US, and bipolar I disorder in EU.

Teaching Biostatistics in School of Public Health (SPH)

company merger and acquisition

Experience: - Neuroscience (schizophrenia, bipolar mania, negative symptoms of schizophrenia) - Working in an environment during company merger and acquisition

Experience: - Neuroscience (schizophrenia) - Analgesia (post surgical dental pain) - Anesthesia/woman's health